Moderna announced Dec. 12 that its chief commercial officer, will step down. The company is planning several commercial product launches in 2024 and 2025, and noted that this strategic reorganization of leadership is an adjustment to help it align with…

Eight drugs had price increases so steep that they cost health insurers nearly $1.3 billion from 2021 to 2022, according to a Dec. 11 report from the Institute for Clinical and Economic Review.

Pfizer will donate the royalty rights from sales of cancer drug Bavencio to the American Association for Cancer Research starting in January.

Nitazenes, a group of highly potent, synthetic drugs made in the 1950s as opioid analgesics, are becoming more commonly used in street drugs. In some cases, it can even be 10 times more potent than fentanyl.

Pharmaceutical maker and biotechnology company Novartis is reporting positive topline results from a phase 3 trial of a drug to treat a rare kidney disease.

The FDA made a historic approval Dec. 8 when it cleared Casgevy, the nation's first medicine based on CRISPR gene-editing technology, as a treatment for sickle cell disease. Its makers are now working with hospitals to establish a network of…

On Dec. 8, the FDA approved the nation's first medicine based on CRISPR gene-editing technology to be used as a treatment for patients with sickle cell disease, a major scientific advancement that opens the door for future gene therapy approvals…

Walgreens will expand treatment and testing options for COVID-19 and the flu, the company announced Dec. 7.

After a nearly nine-month review, the Biden administration has determined it has the authority to seize the patents of certain high-priced drugs developed with taxpayer funds — a policy known as march-in rights. 

Out of the hundreds of new drugs entering the U.S. market, eight made tailwinds in the healthcare industry, according to GoodRx.